Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Lixisenatide44 residuesHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSKKKKKKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Adlyxin, Lyxumia, AVE0010
Six thousand patients and a three-hour half-life tell the story of lixisenatide. This 44-amino-acid GLP-1 receptor agonist, derived from Gila monster venom, binds its target receptor four times harder than native GLP-1. The ELIXA cardiovascular outcomes trial confirmed cardiac safety across 6,068 people with recent acute coronary syndrome. Standalone Adlyxin left the US market in January 2023, but lixisenatide lives on inside Soliqua 100/33 (the fixed-ratio combination with insulin glargine). Endocrinologists prescribe it for patients who need postprandial glucose control without the round-the-clock receptor activation that long-acting GLP-1 agonists deliver.
The GetGoal clinical program ran 11 Phase III trials and confirmed what the pharmacology predicted: a short-acting GLP-1 agonist hits postprandial glucose harder than fasting glucose. Lixisenatide (Adlyxin in the US, Lyxumia in the EU, CAS 320367-13-3) is a synthetic 44-amino-acid peptide built on the exendin-4 backbone from Heloderma suspectum venom. Structural tweaks at the C-terminus, deletion of proline-38 and addition of six lysine residues, give it roughly four-fold higher GLP-1 receptor binding affinity than the native incretin hormone. Sanofi secured EU marketing authorization in 2013, followed by FDA approval in July 2016. The approximately three-hour half-life separates lixisenatide from semaglutide and dulaglutide. That short duration translates into strong but transient gastric emptying delay, which means postprandial glucose drops are most pronounced after the meal closest to injection. Long-acting agents eventually lose that gastric emptying effect through tachyphylaxis; lixisenatide keeps it because receptor occupancy is intermittent. Across the GetGoal trials, HbA1c fell 0.5 to 1.0 percent with weight loss of 0.4 to 2.7 kg. Not blockbuster numbers compared to newer GLP-1 drugs, but meaningful for patients already on basal insulin who need the postprandial piece filled in. The ELIXA trial tracked 6,068 patients with recent acute coronary syndrome for a median of 25 months and landed on a hazard ratio of 1.02 (95% CI 0.89 to 1.17) for major cardiac events. Cardiovascular neutral, not cardioprotective. Standalone Adlyxin was pulled from the US market on January 1, 2023. Soliqua 100/33 (lixisenatide plus insulin glargine) remains available and is the primary access route in the US. Meanwhile, the LIXIPARK Phase 2 trial flagged a surprise: possible slowing of motor progression in Parkinson's disease (MDS-UPDRS III difference of 3.08 points vs. placebo, p=0.007). Phase 3 follow-up is pending.
Lixisenatide locks onto the GLP-1 receptor on pancreatic beta cells with about four times the affinity of native glucagon-like peptide-1. That binding triggers Gs-protein-coupled signaling and raises intracellular cyclic AMP levels. Three glucose-dependent effects follow: insulin secretion ramps up when blood sugar is raised, glucagon release from alpha cells drops, and gastric emptying slows enough to delay nutrient absorption after a meal. The three-hour half-life is the key differentiator. Semaglutide and dulaglutide keep the GLP-1 receptor occupied around the clock, and the gastric emptying effect wears off through tachyphylaxis within weeks. Lixisenatide produces intermittent receptor occupancy instead. Peak plasma concentration arrives 1 to 3.5 hours post-injection, right around the time of the first meal. Gastric emptying slows substantially during that window and then recovers. This on-off pattern preserves the postprandial glucose benefit long-term, which is why lixisenatide punches above its weight class on post-meal glucose control relative to its modest HbA1c effect. Structurally, the peptide traces back to exendin-4 from Gila monster venom. The C-terminal modifications (proline-38 deletion, six added lysine residues) protect it from dipeptidyl peptidase-4. DPP-4 chews through native GLP-1 in about two minutes; lixisenatide lasts hours. Elimination happens through glomerular filtration and proteolytic breakdown in the kidneys, which is why renal impairment matters for dosing decisions.
Effective short-acting GLP-1 agonist for postprandial glucose reduction in T2DM; confirmed cardiovascular-neutral in ELIXA; Phase 2 signal for slowing Parkinson's motor progression (LIXIPARK 2024) warrants Phase 3 follow-up.
ELIXA cardiovascular outcomes trial (NEJM 2015, n=6,068 T2DM + recent ACS; HR 1.02, 95% CI 0.89–1.17) + GetGoal Phase III program (11 trials, HbA1c -0.5 to -1.0%, weight -0.4 to -2.7 kg)
Modest HbA1c and weight-loss effect vs. long-acting GLP-1 agonists; standalone US product (Adlyxin) discontinued Jan 2023; LIXIPARK Parkinson's result requires Phase 3 confirmation; ~70% antibody formation rate (non-neutralizing in most).
Minimal community discussion post-US discontinuation. Previously reported as effective for glucose control with manageable GI effects. No established off-label protocols circulating.
Standalone product discontinued; minimal active community. FDA-label dosing is effectively the only protocol in use. No community-developed protocols or stacks identified.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mcg | Daily |
| Moderate | 20mcg | Daily |
| Aggressive | 20mcg | Daily |
Lixisenatide comes in a pre-filled pen. No vials, no reconstitution, no bacteriostatic water math. The green starter pen delivers 10 mcg per click (14 doses per pen). The burgundy maintenance pen delivers 20 mcg per click (14 doses per pen). Each pen gets discarded 14 days after first use regardless of how many doses remain. Store unused pens in the refrigerator at 2 to 8 degrees Celsius. After the first injection from a pen, keep it at room temperature below 30 degrees Celsius for up to 14 days. Do not freeze. Attach a new needle before each injection and remove it after; storing with a needle attached can cause air bubbles and dose inaccuracy. The timing detail that most people miss: inject within 60 minutes before your first meal of the day. Not after the meal. Not with the meal. Before. The postprandial glucose benefit depends on the gastric emptying delay kicking in before food arrives. If you take oral contraceptives, warfarin, levothyroxine, or any narrow-therapeutic-index drug, take those pills at least one hour before lixisenatide or 11 hours after.
Intended for continuous daily use as a chronic diabetes therapy. No cycling protocol needed. If therapy is interrupted for more than 14 days, restart with 10 mcg daily for 14 days before returning to 20 mcg maintenance dose.
Lixisenatide is an FDA-approved chronic therapy for T2DM: continuous daily dosing is intended with no cycling off periods. Cycling is not clinically indicated. However, if therapy is interrupted for >14 consecutive days, re-titration starting at 10 mcg x 14 days is required before returning to 20 mcg maintenance, to restore GI tolerability.
Or use the universal Peptide Calculator for any peptide.
Expected: HbA1c reduction 0.5-1.0% from baseline; weight loss 0.4-2.7 kg; marked postprandial glucose improvement particularly after the first meal of the day.
Monitor: Check HbA1c at 3 months and every 6 months; monitor fasting and postprandial glucose; renal function (eGFR) periodically given renal elimination.
Remove one pre-filled pen from the refrigerator (green starter pen for days 1 through 14, burgundy maintenance pen from day 15 onward). Let it reach room temperature for a few minutes.
It should be clear and colorless. Do not use if cloudy, discolored, or containing particles.
Remove both the outer and inner needle caps.
If using a new pen for the first time, prime by dialing to the designated mark and pressing the injection button until a drop appears at the needle tip. This removes air from the cartridge.
Select your dose (each pen delivers one fixed dose per activation, 10 mcg for the green pen, 20 mcg for the burgundy pen).
Rotate sites with each injection to reduce injection site reactions.
Pinch the skin, insert the needle at a 90-degree angle, and press the injection button fully. Hold for 5 to 10 seconds before withdrawing.
Remove the needle using the outer cap and dispose of it in a sharps container. Store the pen without a needle attached.
Timing: inject within 60 minutes before the first meal of the day. If a dose is missed, inject within 60 minutes before the next meal. Never inject after a meal or double-dose.
Discard the pen 14 days after the first use, even if doses remain.
FDA-approved fixed-ratio combination. Basal insulin (glargine) covers fasting glucose; lixisenatide targets postprandial spikes. LixiLan trials showed superior HbA1c reduction vs. either component alone.
Soliqua 100/33 pen: titrate insulin glargine units per label; lixisenatide dose is fixed-ratio
Standard T2DM combination; additive glucose-lowering via complementary mechanisms (metformin: hepatic glucose production; lixisenatide: postprandial). No pharmacokinetic interaction.
Complementary mechanisms: SGLT-2i reduces fasting glucose and has cardiovascular/renal benefits; lixisenatide targets postprandial glucose. Additive weight and HbA1c reduction in clinical practice.
Same class (GLP-1 receptor agonist). Concurrent use provides no additive glycemic benefit, doubles GI adverse effects, and is not studied. Contraindicated per FDA labeling.
Do not combineSame class (GLP-1 receptor agonist). Class duplication. No evidence of benefit; increased nausea, vomiting, and hypoglycemia risk.
Do not combineSame class (GLP-1 receptor agonist, also exendin-4 derivative). Structural overlap and receptor competition. Concurrent use contraindicated.
Do not combineIncreased hypoglycemia risk when combined with lixisenatide. FDA label recommends considering sulfonylurea dose reduction when initiating lixisenatide.
Pricing updated 2026-04-09
Pancreatitis is the risk that demands the most attention. Across all lixisenatide clinical trials, 21 pancreatitis cases occurred in treated groups vs. 14 in controls. The absolute incidence is low, but any persistent severe abdominal pain, especially radiating to the back with nausea and vomiting, requires immediate discontinuation and amylase/lipase testing. Gastrointestinal effects are common and predictable for the GLP-1 class. Pooled trial data pinned nausea at 25% (vs. 10% placebo), vomiting at 10% (vs. 2% placebo), and diarrhea at 10% (vs. 8% placebo). These numbers reflect the initiation and dose-escalation phases; most patients see GI symptoms improve within 2 to 4 weeks. The 14-day titration at 10 mcg before stepping up to 20 mcg exists specifically to reduce GI severity. Skipping that titration is asking for trouble. Hypoglycemia hit about 9% of patients (vs. 8% placebo) when lixisenatide was used alone. That risk climbs when you add sulfonylureas or insulin. The FDA label recommends considering sulfonylurea dose reduction when starting lixisenatide. Injection site reactions occurred in 3.9% of patients. Most were mild, localized, and self-resolving. Anti-lixisenatide antibodies developed in approximately 70% of trial participants. That sounds alarming, but these antibodies were mostly non-neutralizing and did not affect glycemic control or safety in the majority of cases. If unexplained efficacy loss occurs, antibody titer testing is an option. Acute kidney injury is a secondary risk linked to dehydration from severe GI episodes. Anyone with baseline renal impairment (eGFR below 30) needs closer monitoring; the drug is contraindicated at eGFR below 15. Unlike semaglutide and liraglutide, lixisenatide does not carry a boxed warning for thyroid C-cell tumors. The precautionary contraindication for personal or family history of medullary thyroid carcinoma or MEN2 remains on the label. Pregnant or breastfeeding individuals should not use lixisenatide. Animal studies flagged adverse fetal effects, and no adequate human data exists. When to get medical help: persistent severe abdominal pain, signs of allergic reaction (facial swelling, difficulty breathing, rash), or symptoms of severe dehydration. When to stop: confirmed pancreatitis, anaphylaxis, or eGFR drop below 15.
Verify Lixisenatide dosing and safety with a second opinion
Soliqua 100/33 (lixisenatide + insulin glargine) remains an FDA-approved pharmaceutical product, subject to full manufacturing and quality standards. Standalone Adlyxin is discontinued in the US. Any compounded lixisenatide (not standard in the US) would carry significantly higher quality risk.
| Test | When | Target |
|---|---|---|
| HbA1c | At 3 months after initiation, then every 6 months | <7.0% for most T2DM patients (individualize per ADA guidelines) |
| Fasting plasma glucose & postprandial glucose (1-2h after first meal) | Weekly during titration, monthly during maintenance or per clinical judgment | Fasting: 80-130 mg/dL; 2h postprandial: <180 mg/dL (ADA) |
| Serum creatinine / eGFR | At baseline and annually (or if dehydration/severe GI event occurs) | eGFR >15 mL/min required; use with caution eGFR 15-30 |
| Amylase / lipase (if abdominal pain) | Immediately if persistent severe abdominal pain, nausea, or vomiting develops | — |
| Body weight | Monthly during first 6 months | — |
Primary efficacy marker for T2DM indication; expected reduction 0.5-1.0% from baseline.
Lixisenatide predominantly lowers postprandial glucose; fasting glucose monitoring identifies need for basal insulin adjustment (especially in Soliqua users).
Lixisenatide is renally eliminated; dose not studied in eGFR <15 mL/min. Severe dehydration from GI side effects can precipitate acute kidney injury.
GLP-1 class pancreatitis risk; 21 cases in lixisenatide arms vs 14 placebo across all trials. Discontinue immediately if pancreatitis confirmed.
Modest weight loss (0.4-2.7 kg) is a secondary benefit; tracking helps assess overall metabolic response.
Starting dose of 10 mcg daily. Appetite suppression begins. Nausea is most common during this initiation phase and typically mild. Postprandial glucose improvements are noticeable within the first few days, especially after the meal following injection.
Dose increase to 20 mcg daily. Stronger postprandial glucose control. GI side effects may briefly recur with the dose increase but usually resolve within a week. Early HbA1c improvements beginning.
Steady-state therapeutic effect. HbA1c reductions of 0.5-0.8% typically measurable. Modest weight loss of 1-2 kg. Nausea and other GI effects largely resolved by this point.
Full therapeutic benefit reached. HbA1c reduction of 0.5-1.0% from baseline across GetGoal trials. Weight stable or modestly lower (0.4-2.7 kg loss depending on background therapy). Postprandial glucose control well established.
Days 1 through 14 (10 mcg initiation): Postprandial glucose readings start dropping within the first week, particularly after the meal following injection. Nausea affects about 25% of users during this window (compared to 10% on placebo) and typically peaks in the first two weeks. HbA1c changes won't show up on lab work yet; this phase is about GI adaptation and establishing the postprandial benefit. Days 15 through 30 (20 mcg escalation): Switching to the burgundy maintenance pen brings stronger post-meal glucose suppression. Nausea may briefly return with the dose increase but settles within one to two weeks for most people. Injection site reactions (about 3.9% incidence) can appear during this phase. Weeks 5 through 12 (steady state): GI side effects are largely behind you by week five or six. HbA1c reductions of 0.5 to 0.8 percent become measurable on lab work. Weight loss of 0.5 to 1.5 kg is typical. Appetite reduction persists at a modest level; this isn't the dramatic suppression that semaglutide produces. Weeks 12 through 24 (full therapeutic benefit): HbA1c reduction settles at 0.5 to 1.0 percent from baseline, consistent with the GetGoal trial program results. Weight loss plateaus somewhere between 0.4 and 2.7 kg depending on background therapy. Postprandial glucose control is well established. Tolerability is generally good for patients who made it through the initial GI phase.
Postprandial glucose reduction begins within days via gastric emptying delay and glucose-dependent insulin stimulation. HbA1c changes not yet measurable.
Glucose readings after meals noticeably lower, particularly after the first meal of the day. Blood sugar improvements evident on glucometer within the first week.
Stronger postprandial glucose suppression. GI side effects may briefly recur with dose increase but resolve within 1-2 weeks in most patients.
Enhanced meal-time glucose control. Some users report temporary return of nausea with the dose increase.
Stable pharmacodynamic effect. HbA1c reductions of 0.5-0.8% measurable. Weight loss of 0.5-1.5 kg typical. GI side effects largely resolved.
Consistent glucose control. GI side effects resolved. Modest appetite reduction persists.
Maximum HbA1c reduction: 0.5-1.0% from baseline (GetGoal trials). Weight loss plateau at 0.4-2.7 kg. Sustained postprandial glucose control.
Stable glycemic outcomes. Some report weight loss leveling off. Long-term tolerability generally good for those who pass the initial GI phase.
Source: FDA prescribing information; mean terminal half-life ~3 hours after multiple-dose SC administration
Loading the interactive decay curve.
Lixisenatide is an FDA-approved prescription medication for type 2 diabetes (Adlyxin, approved July 2016). The standalone Adlyxin product was voluntarily discontinued from the US market effective January 1, 2023. The only remaining FDA-approved source of lixisenatide in the US is Soliqua 100/33 (lixisenatide plus insulin glargine fixed-ratio combination). In Europe, the standalone product Lyxumia retains marketing authorization from the EMA. Lixisenatide is not on the WADA Prohibited List. Athletes should verify current status before competition. Compounded standalone lixisenatide is not widely available in the US due to discontinued API supply chains. Any product obtained outside of a regulated pharmacy supply chain carries unknown quality and safety risk. This content is for informational purposes only. It does not replace medical advice, diagnosis, or treatment from a licensed healthcare provider. Always consult a physician before starting or changing any medication.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
